Douglas Reynolds is President of Sunovion Pharmaceuticals Canada Inc., a subsidiary of Sunovion Pharmaceuticals, Inc., a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. He leads a cross-functional team responsible for driving the growth of products in the Sunovion Pharmaceuticals Canada Inc. portfolio. In addition, he is responsible for guiding the company’s overall business strategy in Canada.
Mr. Reynolds has more than 30 years of pharmaceutical industry experience. Prior to joining Sunovion, he led Oryx Pharmaceuticals, Inc. since its founding in 2001. Prior to starting Oryx, Mr. Reynolds held senior sales and marketing positions with several pharmaceutical companies, including Sanofi, Roche, Syntex and Lederle Laboratories. Mr. Reynolds has been responsible for numerous product launches and brand building across multiple therapeutic categories.
Mr. Reynolds holds a Bachelor of Science degree from the University of Toronto and a Master of Business Administration from York University in Toronto.